



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

MAB's - Anti-IL, Anti-IgE, Anti-TLSP

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:		Prescriber Name:	
Member ID Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Member Phone Number:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: <input type="checkbox"/> Medicaid <input type="checkbox"/> CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code:	Diagnosis:		
<i>Jefferson Health Plans' maximum approval time is 12 months but may be less depending on the criteria..</i>			

Please attach any pertinent medical history including labs and information for this member that may support approval.
Please answer the following questions and sign.

Q1. The request is for renewal of a prior authorization for the MABs - Anti-IL, Anti-IgE, Anti-TSLP that was previously approved. If YES, go to 18.

Yes

No

Q2. The member meets ALL of the following:

- Is prescribed the requested drug for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication
- Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature
- Is prescribed by or in consultation with an appropriate specialist (i.e., pulmonologist, allergist, immunologist, dermatologist, hematologist/oncologist, rheumatologist, etc.)
- If currently using a different MAB - Anti-IL, Anti-IgE, Anti-TSLP than requested, will discontinue the other MAB - Anti-IL, Anti-IgE, Anti-TSLP prior to starting the requested agent

Q3. For a non-preferred MAB - Anti-IL, Anti-IgE, Anti-TSLP, BOTH of the following: If YES, go to 5.

MAB's - Anti-IL, Anti-IgE, Anti-TLSP

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

<input type="checkbox"/> Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred MABs - Anti-IL, Anti-IgE, Anti-TSLP approved or medically accepted for the beneficiary's indication	<input type="checkbox"/> For a non-preferred MAB - Anti-IL, Anti-IgE, Anti-TSLP with a corresponding biosimilar/brand biologic/unbranded biologic that is preferred on the Preferred Drug List (PDL), has a history of therapeutic failure of or a contraindication or an intolerance to the preferred corresponding biosimilar/brand biologic/unbranded biologic that would not be expected to occur with the requested drug
---	---

Q4. Has a current history (within the past 90 days) of being prescribed the same non-preferred MAB - Anti-IL, Anti-IgE, Anti-TSLP (does not apply to non-preferred MABs - Anti-IL, Anti-IgE, Anti-TSLP when a corresponding biosimilar/brand biologic/unbranded biologic is preferred) See the PDL for the list of preferred MABs - Anti-IL, Anti-IgE, Anti-TSLP at: <https://papdl.com/preferred-drug-list>

Yes No

Q5. For a diagnosis of ASTHMA, BOTH of the following:

If YES, go to 14.

<input type="checkbox"/> Has an asthma severity that is consistent with the FDA-approved indication for the prescribed MAB - Anti-IL, Anti-IgE, Anti-TSLP despite maximal therapeutic doses of or contraindication or intolerance to standard asthma controller drugs based on current national treatment guidelines for the diagnosis and management of asthma	<input type="checkbox"/> Will use the requested MAB - Anti-IL, Anti-IgE, Anti-TSLP in addition to standard asthma controller drugs as recommended by current national treatment guidelines for the diagnosis and management of asthma
---	---

Q6. For a diagnosis of CHRONIC SPONTANEOUS URTICARIA, has a history of urticaria for a period of at least six weeks.

Yes No

Q7. The member meets ONE of the following:

MAB's - Anti-IL, Anti-IgE, Anti-TLSP

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

<input type="checkbox"/> Requires systemic steroids to control urticarial symptoms	<input type="checkbox"/> Has a history of therapeutic failure of or a contraindication or an intolerance to maximum tolerated doses of an H1 antihistamine taken for at least two weeks
--	---

Q8. For a diagnosis of EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA), has a diagnosis of EGPA supported by BOTH of the following:

If NA, go to 12.

<input type="checkbox"/> A history of asthma	<input type="checkbox"/> A history of absolute blood eosinophil count 1000 cells/microL or blood eosinophil level >10% of leukocytes
--	--

Q9. A history of at least ONE of the following:

<input type="checkbox"/> Histopathological evidence of ONE of the following: Eosinophilic vasculitis, perivascular eosinophilic infiltration, eosinophil-rich granulomatous inflammation <input type="checkbox"/> Neuropathy, mono or poly (motor deficit or nerve conduction abnormality) <input type="checkbox"/> Pulmonary infiltrates, non-fixed <input type="checkbox"/> Sino-nasal abnormality <input type="checkbox"/> Cardiomyopathy	<input type="checkbox"/> Glomerulonephritis <input type="checkbox"/> Alveolar hemorrhage <input type="checkbox"/> Palpable purpura <input type="checkbox"/> Positive test for ANCA
--	---

Q10. ONE of the following:

<input type="checkbox"/> Requires systemic glucocorticoids to maintain remission	<input type="checkbox"/> Has a contraindication or an intolerance to systemic glucocorticoids
--	---

Q11. For a beneficiary with severe EGPA as defined by national treatment guidelines, has a history of therapeutic failure of or a contraindication or an intolerance to rituximab or cyclophosphamide.

<input type="checkbox"/> Yes	<input type="checkbox"/> No
------------------------------	-----------------------------

Q12. For a diagnosis of HYPEREOSINOPHILIC SYNDROME (HES), all of the following:

MAB's - Anti-IL, Anti-IgE, Anti-TLSP

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

<input type="checkbox"/> Has FIP1L1-PDGFR α -negative HES with organ damage or dysfunction <input type="checkbox"/> Has a blood eosinophil count 1000 cells/microL <input type="checkbox"/> Requires or has required systemic glucocorticoids to maintain remission OR has a contraindication or an intolerance to systemic glucocorticoids
--

Q13. For all other diagnoses, has a history of therapeutic failure of or a contraindication or an intolerance to first line therapy(ies) if applicable according to consensus treatment guidelines <input type="checkbox"/> Yes <input type="checkbox"/> No

Q14. For Xolair (omalizumab) for a diagnosis of asthma, has a diagnosis of allergen-induced asthma (allergic asthma confirmed by either a positive skin test or radioallergosorbent test) to an unavoidable perennial aeroallergen (e.g., pollen, mold, dust mite, etc.). <input type="checkbox"/> Yes <input type="checkbox"/> No
--

Q15. For Cinqair (reslizumab) for a diagnosis of asthma with an eosinophilic phenotype, has an absolute blood eosinophil count 400 cells/microL. <input type="checkbox"/> Yes <input type="checkbox"/> No

Q16. For Nucala (mepolizumab) for a diagnosis of asthma, has asthma with an eosinophilic phenotype with absolute blood eosinophil count 150 cells/microL. <input type="checkbox"/> Yes <input type="checkbox"/> No
--

Q17. For Fasentra (benralizumab), has asthma with an eosinophilic phenotype with absolute blood eosinophil count 150 cells/microL. <input type="checkbox"/> Yes <input type="checkbox"/> No

Q18. The member meets ALL of the following: <input type="checkbox"/> Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature <input type="checkbox"/> Is prescribed a MAB - Anti-IL, Anti-IgE, Anti-TSLP by or in consultation with an appropriate specialist (i.e., pulmonologist, allergist, immunologist, dermatologist, rheumatologist, etc.)
--



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

MAB's - Anti-IL, Anti-IgE, Anti-TLSP

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------

Is not using the requested MAB - Anti-IL, Anti-IgE, Anti-TSLP in combination with another MAB - Anti-IL, Anti-IgE, Anti-TSLP

Q19. For a diagnosis of asthma, BOTH of the following:

Has measurable evidence of improvement in the severity of the asthma condition

Continues to use the requested MAB - Anti-IL, Anti-IgE, Anti-TSLP in addition to standard asthma controller drugs as recommended by current national treatment guidelines for the diagnosis and management of asthma

Q20. For a diagnosis of chronic spontaneous urticaria, BOTH of the following:

Experienced improvement of symptoms

Has a documented rationale for continued use

Q21. For a diagnosis of HES or EGPA, has ONE of the following:

Measurable evidence of improvement in disease activity

Reduction in use of systemic glucocorticoids for this indication

Q22. For a non-preferred MAB - Anti-IL, Anti-IgE, Anti-TSLP with a corresponding biosimilar/brand biologic/unbranded biologic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred corresponding biosimilar/brand biologic/unbranded biologic that would not be expected to occur with the requested drug. See the PDL for the list of preferred MABs - Anti-IL, Anti-IgE, Anti-TSLP at: <https://papdl.com/preferred-drug-list>.

Yes No

Q23. Additional Information:

Prescriber Signature

Date



MEDICAID / CHIP
PHARMACY PRIOR AUTHORIZATION REQUEST FORM

MAB's - Anti-IL, Anti-IgE, Anti-TLSP

Phone: 866-841-7659

Fax back to: 866-240-3712

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Member Name:	Prescriber Name:
--------------	------------------